IntelliCell BioSciences Has Engaged inVentiv Clinical as CRO for
Osteoarthritis IND Lead by Dr. James Andrews
NEW YORK, NY--(Marketwired - Apr 14, 2014) - IntelliCell
BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a
regenerative medicine company utilizing adult autologous
stomovascular cells (SVCs) derived from the blood vessels found in
adipose tissue, announced today that it has engaged inVentiv Health
Clinical as the Clinical Research Organization (CRO) for the
conduct of a clinical trial in osteoarthritis of the knee under an
Investigational New Drug Application (IND). Dr. James
Andrews, the legendary orthopedic surgeon will be the principal
investigator for the study.
IntelliCell BioSciences and Dr. James Andrews are developing the
investigational clinical study protocols in collaboration with
inVentiv Clinical, functioning as the CRO. The clinical trial
will be conducted at the Pensacola Center of the Andrews' Research
and Educational Institute in conjunction with Dr. Adam Anz and Dr.
Josh Hackel, prominent physicians at the Institute. To date,
IntelliCell's technology for isolating stromal vascular fraction
cells from the vasculature of adipose tissue has been used to
successfully treat over 60 knees with results lasting as long as 5
years.
IntelliCell's Chief Executive Officer, Dr. Steven Victor,
remarked, "This is a pivotal point for IntelliCell BioSciences as
it will be what we believe to represent the first of many clinical
trials that the company will undertake and establish the company as
a leader in the cellular therapy segment of the biotech
industry. This IND study is important for proving the company's
patented technology of Ultrasonic Cavitation as a method of
separating stromal vascular fraction cells from lipoaspirate. We
believe that IntelliCell's Stromal Vascular Fraction Cells will
offer people with OA a new and improved approach to gaining
significant improvements in their qualities of life. We at
IntelliCell are excited to have this opportunity to work with the
distinguished Sports Medicine Orthopedic Surgeon, Dr. James
Andrews, who will be the principal investigator of this clinical
trial."
According to Raymond Hill, President of inVentiv Clinical,
"inVentiv Clinical has extensive therapeutic experience in general
pain and osteoarthritis programs and a focus on partnering with
innovative bioscience companies. We are looking forward to our
working with Dr. Andrews and contributing to advances in the
treatment of osteoarthritis in knees."
Dr. James Andrews said, "We are excited that we will have the
opportunity to work with inVentiv Clinical Health as the CRO for
our IND study of osteoarthritis of the knee using IntelliCell's
technology. It will be research like this at the Andrews' Research
and Educational Institute in collaboration with IntelliCell
BioSciences and inVentiv that will further our research in the use
of the biologics for the treatment of the osteoarthritic
knee. We believe, based on antidotal evidence of others, that
this cellular therapy has the potential to be a game changer."
About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company
focused on the expanding regenerative medical markets using adult
autologous stromal vascular fraction cells (SVFCs) derived from the
blood vessels in the adult adipose tissue. IntelliCell BioSciences
has developed its own patented technology and protocol to separate
adult autologous vascular cells from adipose tissue without the use
of enzymes. IntelliCell will also be seeking to develop
technology-licensing agreements with technology developers,
universities, and international business entities.
About Dr. James Andrews
Dr. James Andrews is internationally known and recognized for
his scientific and clinical research contributions in knee,
shoulder and elbow injuries, as well as his skill as an orthopedic
surgeon.
Dr. Andrews is a founding partner and medical director for the
Andrews Institute in Gulf Breeze, Florida. In addition, he is a
founding member of the American Sports Medicine Institute
(ASMI).
Dr. Andrews has been the mentor for more than 250
orthopedic/sports medicine fellows and more than 45 primary care
sports medicine fellows. Involved in education and research in
sports medicine and orthopedic surgery, he has made major
presentations on every continent, and has authored numerous
scientific articles and books.
About Osteoarthritis Arthritis of the Knee
Osteoarthritis (OA) also known as degenerative arthritis or
degenerative joint disease or osteoarthrosis, is a group of
mechanical abnormalities involving degradation of joints, including
articular cartilage and subchondral bone. Symptoms may include
joint pain, tenderness, stiffness, locking, and sometimes an
effusion. A variety of causes -- hereditary, developmental,
metabolic, and mechanical deficits -- may initiate processes
leading to loss of cartilage. When bone surfaces become less well
protected by cartilage, bone may be exposed and damaged. As a
result of decreased movement secondary to pain, regional muscles
may atrophy, and ligaments may become more lax.
Treatment generally involves a combination of exercise,
lifestyle modification, and analgesics. If pain becomes
debilitating, joint replacement surgery may be used to improve the
quality of life. OA is the most common form of arthritis, and the
leading cause of chronic disability in the United States. It
affects about 1.9 million people in Australia, 8 million people in
the United Kingdom and nearly 27 million people in the United
States.
About inVentiv Health Clinical
inVentiv Health Clinical is a leading provider of global drug
development services to pharmaceutical, biotechnology, generic
drug, and medical device companies, offering therapeutically
specialized capabilities for Phase I-IV clinical development,
bioanalytical services, and strategic resourcing from a single
clinical professional to an entire functional team. With 6,500
passionate employees supporting clients in more than 70 countries,
inVentiv Health Clinical works to accelerate high quality drug
development programs of all sizes around the world. inVentiv Health
Clinical is part of inVentiv Health, Inc., a life science knowledge
and services company purpose-built for the new healthcare
marketplace. inVentiv has created a new model by converging a vast
range of essential services to fully align with our client's
development and commercialization goals. For more information,
visit www.inventivhealthclinical.com.
Forward-Looking Statements Certain statements set forth in this
press release constitute "forward-looking statements."
Forward-looking statements include, without limitation, any
statement that may predict, forecast, indicate, or imply future
results, performance or achievements, and may contain the words
"estimate," "project," "intend," "forecast," "anticipate," "plan,"
"planning," "expect," "believe," "will likely," "will reach," "will
change," "will soon," "should," "could," "would," "may," "can" or
words or expressions of similar meaning. Such statements are not
guarantees of future performance and are subject to risks and
uncertainties that could cause the company's actual results and
financial position to differ materially from those included within
the forward-looking statements. Forward-looking statements involve
risks and uncertainties, including those relating to the Company's
ability to grow its business. Actual results may differ materially
from the results predicted and reported results should not be
considered as an indication of future performance. The potential
risks and uncertainties include, among others, the Company's
limited operating history, the limited financial resources,
domestic or global economic conditions, activities of competitors
and the presence of new or additional competition, and changes in
Federal or State laws. More information about the potential factors
that could affect the Company's business and financial results is
included in the Company's filings, available via the United States
Securities and Exchange Commission.
Contact: IntelliCell BioSciences, Inc. Investor Relations Anna
Rhodes Email Contact (646) 576-8308